NMC founder Shetty considers selling UAE-based drugs firm, sources say
Shetty has been under financial pressure after pledging shares in UAE-based hospital operator NMC
Reuters News - 03-Mar-2020
Neopharma LLC
Last updated on: 04 October 2019
fast facts
Business SummaryManufacture of generic drugs; provides marketing and research services.Country of IncorporationUAEOwnership TypeForeignEstablished In2003Primary SectorHealth CareNumber of Employees445Latest News
healthcare
Neopharma and GSK partnership produces first line of medicines packaged in UAE
Partners Neopharma & GSK have produced the first batch of medicines at local Secondary Packaging stage
Press Release - 11-Jan-2020Gsk and Neopharma partnership produces first line of medicines packaged in the UAE as part of vision to become a regional manufacturing hub
Partners GSK and Neopharma have produced the first batch of medicines at local Secondary Packaging stage
Press Release - 08-Jan-2020GSK, Neopharma launch UAE-made medicines
This first batch includes 35,000 packages of medicine
TradeArabia - 08-Jan-2020Neopharma forms JV with Elevar Therapeutics for commercialization of Oncology NCE
Neopharma a global pharmaceutical company will undertake commercializing responsibility through its presence in various countries of MENA & India
Press Release - 31-Oct-2019Contact details
Primary address
Building 89-95Mussafah Street
Industrial City of Abu Dhabi (ICAD), Plot A-1
72900
UAE
Abu Dhabi
Region
Abu DhabiCONTACT
- Tel: +971 2-550-1000
- Fax: +971 2-550-1199
- Email: neopharma@neopharma.ae
- www.neopharmauae.com
Find Out More Information
Access the most comprehensive database of companies and officers in the Middle East and North Africa, covering all major sectors and industries, from Refinitiv.
Company information provided by Refinitiv
Refinitiv research team update company information from primary sources (company annual reports, press releases, company websites, corporate briefings, official statements/interviews) and reliable secondary sources (stock markets, reliable third party publications).